JPD:GBA帕金森病患者,体位性低血压明显

2022-05-19 Freeman MedSci原创

GBA-PD患者从仰卧位转变为直立位时收缩压下降得更明显

葡萄糖苷酶(GBA)基因的变异是帕金森病(PD)发病最常见的遗传风险因素。在一项包括1,360名参与者的大型国际综合基因筛查研究中,8.5%的帕金森病患者被发现携带杂合的GBA变体,其中最常见的是c.1093G>A(p.Glu365Lys,也称为E326K)和c.1223C>T(p.Thr408Met,也称为T369M)。在最近的一项荟萃分析中发现,这两个变异体在非阿什肯纳齐犹太人群中显著增加PD的风险。

图1:论文封面图

直立性低血压(OH)被定义为在站立3分钟内收缩压持续下降至少20毫米汞柱或舒张压下降10毫米汞柱。在PD中,OH的发生率为30-40%,取决于病程和疾病的严重程度。与GBA相关的PD(GBA-PD)患者报告自律神经症状,如OH,比特发性PD(IPD)患者更频繁,程度更严重。

与这些报告相反,一项针对1435名PD患者的大型国际研究和最近的荟萃分析没有发现GBA-PD和IPD患者之间有不同的OH频率;然而,仍然不能确定如何评估OH。

OH与认知能力下降以及姿势不稳和步态困难表型(PIGD)有关。这些临床特征在GBA-PD中也比IPD中更常见。PD中的OH主要是由于心血管症状神经支配导致的肾上腺素缺乏的结果。

以前的一份报告发现,与IPD相比,GBA-PD的心肌(123)I-metaiodo-benzylguanidine摄取量有更大的减少,这表明GBA-PD的交感神经失调更为明显。

为了解决GBA-PD与IPD相比在OH发生率方面的矛盾,德国University of Lubeck的Tatiana Usnich等人,在以前描述的和同时扩大的PD队列中进行了OH分析。他们旨在评估GBA-PD与IPD相比,从仰卧位转为直立位时的血压变化,并捕捉在改变体位时发生的任何相关症状。

与特发性帕金森病患者(IPD)相比,携带葡萄糖脑苷脂酶(GBA)基因变体的帕金森病患者(GBA-PD)更频繁地出现正压症状。

他们对33名GBA-PD和313名IPD患者进行了前瞻性分析。

与IPD患者相比,GBA-PD患者从仰卧位转变为直立位时收缩压下降得更明显

图2:论文结果图

舒张压和心率在组间没有差异。

这项研究为GBA-PD中自律神经系统的明显参与提供了进一步证据。


原文出处:
on behalf of the EPIPARK Study Group, Usnich T, Hanssen H, et al. Pronounced Orthostatic Hypotension in GBA-Related Parkinson’s Disease. JPD. Published online April 28, 2022:1-6. doi:10.3233/JPD-223197

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1239913, encodeId=e0001239913a1, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff9c3032606, createdName=laiminchao, createdTime=Sat Aug 20 08:07:25 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757452, encodeId=f7421e57452f8, content=<a href='/topic/show?id=058e4852e63' target=_blank style='color:#2F92EE;'>#帕金森病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48527, encryptionId=058e4852e63, topicName=帕金森病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a17f37322741, createdName=ms6832696159214430, createdTime=Sat Apr 15 08:51:20 CST 2023, time=2023-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1367433, encodeId=357e136e433cf, content=<a href='/topic/show?id=f4012634656' target=_blank style='color:#2F92EE;'>#低血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26346, encryptionId=f4012634656, topicName=低血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri May 20 05:51:20 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573965, encodeId=7b7415e39654f, content=<a href='/topic/show?id=6b3348526a0' target=_blank style='color:#2F92EE;'>#帕金森病患#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48526, encryptionId=6b3348526a0, topicName=帕金森病患)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri May 20 05:51:20 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220934, encodeId=c1c312209344b, content=111, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43958165571, createdName=ms9000000795072041, createdTime=Thu May 19 14:51:39 CST 2022, time=2022-05-19, status=1, ipAttribution=)]
    2022-08-20 laiminchao

    感谢分享

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1239913, encodeId=e0001239913a1, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff9c3032606, createdName=laiminchao, createdTime=Sat Aug 20 08:07:25 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757452, encodeId=f7421e57452f8, content=<a href='/topic/show?id=058e4852e63' target=_blank style='color:#2F92EE;'>#帕金森病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48527, encryptionId=058e4852e63, topicName=帕金森病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a17f37322741, createdName=ms6832696159214430, createdTime=Sat Apr 15 08:51:20 CST 2023, time=2023-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1367433, encodeId=357e136e433cf, content=<a href='/topic/show?id=f4012634656' target=_blank style='color:#2F92EE;'>#低血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26346, encryptionId=f4012634656, topicName=低血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri May 20 05:51:20 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573965, encodeId=7b7415e39654f, content=<a href='/topic/show?id=6b3348526a0' target=_blank style='color:#2F92EE;'>#帕金森病患#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48526, encryptionId=6b3348526a0, topicName=帕金森病患)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri May 20 05:51:20 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220934, encodeId=c1c312209344b, content=111, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43958165571, createdName=ms9000000795072041, createdTime=Thu May 19 14:51:39 CST 2022, time=2022-05-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1239913, encodeId=e0001239913a1, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff9c3032606, createdName=laiminchao, createdTime=Sat Aug 20 08:07:25 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757452, encodeId=f7421e57452f8, content=<a href='/topic/show?id=058e4852e63' target=_blank style='color:#2F92EE;'>#帕金森病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48527, encryptionId=058e4852e63, topicName=帕金森病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a17f37322741, createdName=ms6832696159214430, createdTime=Sat Apr 15 08:51:20 CST 2023, time=2023-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1367433, encodeId=357e136e433cf, content=<a href='/topic/show?id=f4012634656' target=_blank style='color:#2F92EE;'>#低血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26346, encryptionId=f4012634656, topicName=低血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri May 20 05:51:20 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573965, encodeId=7b7415e39654f, content=<a href='/topic/show?id=6b3348526a0' target=_blank style='color:#2F92EE;'>#帕金森病患#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48526, encryptionId=6b3348526a0, topicName=帕金森病患)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri May 20 05:51:20 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220934, encodeId=c1c312209344b, content=111, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43958165571, createdName=ms9000000795072041, createdTime=Thu May 19 14:51:39 CST 2022, time=2022-05-19, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1239913, encodeId=e0001239913a1, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff9c3032606, createdName=laiminchao, createdTime=Sat Aug 20 08:07:25 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757452, encodeId=f7421e57452f8, content=<a href='/topic/show?id=058e4852e63' target=_blank style='color:#2F92EE;'>#帕金森病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48527, encryptionId=058e4852e63, topicName=帕金森病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a17f37322741, createdName=ms6832696159214430, createdTime=Sat Apr 15 08:51:20 CST 2023, time=2023-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1367433, encodeId=357e136e433cf, content=<a href='/topic/show?id=f4012634656' target=_blank style='color:#2F92EE;'>#低血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26346, encryptionId=f4012634656, topicName=低血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri May 20 05:51:20 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573965, encodeId=7b7415e39654f, content=<a href='/topic/show?id=6b3348526a0' target=_blank style='color:#2F92EE;'>#帕金森病患#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48526, encryptionId=6b3348526a0, topicName=帕金森病患)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri May 20 05:51:20 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220934, encodeId=c1c312209344b, content=111, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43958165571, createdName=ms9000000795072041, createdTime=Thu May 19 14:51:39 CST 2022, time=2022-05-19, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1239913, encodeId=e0001239913a1, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff9c3032606, createdName=laiminchao, createdTime=Sat Aug 20 08:07:25 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757452, encodeId=f7421e57452f8, content=<a href='/topic/show?id=058e4852e63' target=_blank style='color:#2F92EE;'>#帕金森病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48527, encryptionId=058e4852e63, topicName=帕金森病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a17f37322741, createdName=ms6832696159214430, createdTime=Sat Apr 15 08:51:20 CST 2023, time=2023-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1367433, encodeId=357e136e433cf, content=<a href='/topic/show?id=f4012634656' target=_blank style='color:#2F92EE;'>#低血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26346, encryptionId=f4012634656, topicName=低血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri May 20 05:51:20 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573965, encodeId=7b7415e39654f, content=<a href='/topic/show?id=6b3348526a0' target=_blank style='color:#2F92EE;'>#帕金森病患#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48526, encryptionId=6b3348526a0, topicName=帕金森病患)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri May 20 05:51:20 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1220934, encodeId=c1c312209344b, content=111, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43958165571, createdName=ms9000000795072041, createdTime=Thu May 19 14:51:39 CST 2022, time=2022-05-19, status=1, ipAttribution=)]
    2022-05-19 ms9000000795072041

    111

    3

    展开3条回复

相关资讯

JPD:低频率的前庭噪音刺激,或可改善帕金森患者姿势障碍

在接受低强度nGVS治疗的患者中,至少有一半的患者在姿势平衡方面表现出与SR相符的有力改善

JPD:冷漠反映了新发帕金森病的纹状体外多巴胺能变性

孤立的帕金森病患者与纹状体外多巴胺能变性有关。

Neurology:神经丝光与帕金森病的发展和严重程度的关联

血液生物标记物可能有助于早期识别帕金森氏病(PD)、帕金森氏症及PD相关不良结局。近日,研究人员发现Nf-L与临床帕金森病、帕金森症状和身体功能下降有关。Nf-L或为神经退行性变潜在生物标记物。

JPD:人格测试,有助于帕金森病基本分类

早期帕金森病患者的性格使我们能够识别3种患者的表型

JPD:帕金森患者的抑郁发病情况如何?

帕金森患者的患病率多少?

拓展阅读

病例报告|帕金森病合并重症肌无力1例

PD合并MG较为罕见,结合文献复习阐述其可能的共病机制及治疗策略,以期提高临床医生对此合并症的全面认识与诊治能力。关键词 

暨南大学张雪娟/黄莹《AFM》:基于嗅区沉积调控和抗氧化策略的溶性液晶鼻喷雾剂用于改善帕金森病的治疗

本研究构建了一种以溶致液晶(LLC)为基材的搭载帕金森病一线治疗药物LDA和抗氧化药物表没食子儿茶素没食子酸酯(EGCG)的原位凝胶鼻喷剂LDA-EGCG IN。

脑病肠治,再添实锤!| 最新研究发现:靶向脑肠轴,为帕金森病干预策略提供新思路

本文介绍帕金森病等突触核蛋白病,强调脑肠轴机制,如肠道菌群失调可致帕金森样行为。甘露特钠靶向脑肠轴可改善相关症状,基于脑肠轴的整体治疗观或用于更多神经系统疾病。

帕金森病康复训练新方法 | 虚拟现实(VR)

帕金森病(PD)是第二大常见的神经退行性疾病,损害平衡和运动功能,其最主要的病理改变是中脑黑质多巴胺能神经元的变性死亡,由此而引起纹状体DA含量显著性减少而致病。

帕金森病屡获新突破,美国仍有192项在研基金支持(2024)

我们仅对美国国立卫生研究院(NIH)资助的在研帕金森相关项目进行梳理,希望给同仁们的选题思路提供一点启发。

王共强:关注帕金森病的情感淡漠 | AHNA&2024

情感淡漠(apathy)是指一种动机减少的行为状态,临床表现为目标导向行为的减少和不同程度兴趣和情感的降低,并且不是因为意识水平下降引起。

2024 NICE 诊断指南:帕金森病远程监测设备 [DG51]

英国国家卫生与临床优化研究所(NICE,National Institute for Health and Clinical Excellence) · 2024-01-25